Biotech
Tuesday, September 5th, 2023 9:00 am EDT
Dive Brief:
Dive Insight:
Even before reaching market, Palforzia’s development journey was rocky. Originally submitted for FDA review in 2019, the therapy’s application was derailed by the partial shutdown of the federal government that year.
Approval, when granted, came with strings attached, as the FDA ordered Aimmune to sell Palforzia through a risk management program designed to protect people from inadvertent allergic reactions. Initial treatment had to occur in a healthcare setting, with epinephrine on hand.
But Nestlé, which had been investing in Aimmune since 2016, decided to build an allergy treatment business around Palforzia, and housed the treatment in a stand-alone unit.
Limited treatment adoption, hurt by the pandemic and complicated dosing, led to the 2022 strategic review and, in February, Nestlé revealed it had taken an impairment charge of 1.9 billion Swiss francs on Palforzia and Aimmune.
Stallergenes Greer, which specializes in allergy treatments, hopes to turn the product’s fortunes around. “By entering the food allergy space, Stallergenes Greer becomes the first allergen immunotherapy company to offer both respiratory and food allergy treatments,” said CEO Michele Antonelli, in a statement.
Under the deal, which closed on signing, Stallergenes Greer will make unspecified milestone and royalty payments to Nestlé. The companies didn’t disclose whether any upfront cash is involved.
This post has been syndicated from a third-party source. View the original article here.
